Last reviewed · How we verify
Congenital neutropenia
Approved treatments
- Neupogen · University of Chicago
- Neupogen · Amgen
Filgrastim-aafi binds G-CSF receptors on hematopoietic cells, stimulating neutrophil proliferation, differentiation, and functional activation.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Congenital neutropenia patent landscape — cliff calendar, originator estates, attackable patents
- Congenital neutropenia treatment landscape brief
- Congenital neutropenia treatment updates RSS
Frequently asked questions about Congenital neutropenia
What drugs treat Congenital neutropenia?
Tracked treatments include Neupogen.
What is the treatment for Congenital neutropenia?
Standard treatment for Congenital neutropenia includes Neupogen. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Congenital neutropenia patent cliff · Congenital neutropenia CI report
- Treatment: Neupogen · University of Chicago
- Treatment: Neupogen · Amgen
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing